Reckitt Q1 Sales Miss Expectations Amid US Demand Slump

Reckitt Benckiser Group Plc has reported first-quarter sales growth that failed to meet market expectations, primarily due to a downturn in the US over-the-counter drug market. The company's core brands, including Dettol and Strepsils, saw a combined sales increase of 1.3%. This growth figure trailed the 2.8% projection set by analysts, highlighting a struggle to maintain momentum in key Western markets. The shortfall was largely attributed to lackluster demand for cold and flu medications in the United States, which acted as a significant drag on the overall results. Beyond the US, the company faced additional headwinds in the Middle East. Ongoing geopolitical instability in the region hampered supply chains and distribution, further impacting the quarterly performance. Despite these challenges, Reckitt found a silver lining in Asia. When excluding the US over-the-counter drug segment, the company's growth rose to 3.1%, a figure bolstered significantly by double-digit sales increases in China. Investors are now weighing the divergence between the struggling US healthcare segment and the robust growth in China as the company navigates a volatile global macroeconomic environment.